Testing a new drug for toxic epidermal necrolysis (TEN)
Treatments studied
Part of Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests if a drug called daratumumab can help people with a severe skin reaction (SJS/TEN) caused by a medication. It aims to stop the reaction from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You have a severe skin reaction (SJS, TEN, or overlap) caused by a drug, started within the last 7 days
- The reaction is still spreading or getting worse in the last 48 hours
- You cannot have hepatitis B, COPD, or septic shock
- You are not pregnant, breastfeeding, and agree to use birth control if needed
- You have enough white blood cells (PMNs > 1,500)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a steroid (methylprednisolone) and a JAK inhibitor to treat toxic epidermal necrolysis, a severe skin reaction. The goal is to see if adding the JAK inhibitor helps improve outcomes and safety.
This early-phase trial tests stem-cell treatment to help people with severe skin reactions called SJS-TEN. It may reduce ongoing skin damage and help recovery when treatment is started soon after symptoms begin.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
This trial tests a targeted therapy for people with a severe drug reaction called DRESS syndrome. It may help control the overactive immune response and reduce organ damage.
This trial tests a treatment using your own immune cells, modified to target a protein called CD19, for children and teens with juvenile dermatomyositis that hasn't gotten better with standard treatments. The goal is to see if this therapy can help calm the inflammation and improve symptoms.
Hear when a new Toxic Epidermal Necrolysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.